Introduction
Tenecterel is a medication that contains the active ingredient Tenecteplase. It is available in the form of an injection and is used to treat certain medical conditions.
Uses
Tenecterel is primarily prescribed for the treatment of acute ischemic stroke. It is used to dissolve blood clots that are blocking blood flow to the brain. This medication is typically administered as soon as possible after the onset of stroke symptoms to improve outcomes and reduce disability.
Dosage and Administration
The dosage of Tenecterel is determined by a healthcare professional based on the patient’s weight and the severity of the stroke. It is administered as an intravenous (IV) infusion over a specified period of time. The exact dosage and infusion duration will be determined by your healthcare provider.
Mechanism of Action
Tenecteplase, the active ingredient in Tenecterel, belongs to a class of medications known as thrombolytics or clot-busting agents. It works by activating the body’s natural clot-dissolving system to break down the clot that is blocking blood flow to the brain during an acute ischemic stroke. By restoring blood flow, this medication helps to minimize the damage caused by the stroke and improve the patient’s chances of recovery.
Side Effects
Common side effects may include bleeding, which can manifest as nosebleeds, bruising, or blood in the urine or stools. Serious side effects may include severe bleeding, allergic reactions, or stroke-related complications. Seek immediate medical attention if you experience any unusual or severe side effects while using this medication.
Drug Interactions
Tenecterel may interact with other medications, including anticoagulants (blood thinners) and antiplatelet drugs. These interactions can increase the risk of bleeding. Inform your healthcare provider about all the medications you are currently taking, including over-the-counter drugs, supplements, and herbal products, to avoid potential drug interactions.
Precautions
Before using Tenecterel, inform your healthcare provider about any medical conditions you have, especially if you have a history of bleeding disorders, recent surgery, or if you are pregnant or breastfeeding. This medication should be used with caution in patients with a high risk of bleeding, such as those with uncontrolled high blood pressure or active bleeding. Avoid any activities that may increase the risk of injury while using this medication.
Storage
Tenecterel should be stored at the recommended temperature and away from direct sunlight or heat sources. It should be kept out of the reach of children and pets to prevent accidental ingestion or misuse. Check the expiration date before using the medication and to properly dispose of any expired or unused medication according to local regulations.
Patient Tips
- Follow the dosage and administration instructions provided by your healthcare provider.
- Report any unusual or severe side effects to your healthcare provider immediately.
- Keep a record of the date and time of each dose to ensure proper administration.
- Inform your healthcare provider about all the medications you are taking to avoid potential drug interactions.
- Take precautions to avoid injuries that may lead to bleeding while using this medication.
- Store the medication properly and dispose of any expired or unused medication as directed by your healthcare provider or local regulations.
Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.
References
- Tenecteplase (Drugs.com) [Accessed 18 Jun. 2024] (online) Available at:
- Thrombolytic therapy (MedlinePlus) [Accessed 30 Jun. 2024] (online) Available at:
- Wang Y, Li S, Pan Y, Li H, Parsons MW, Campbell BCV, Schwamm LH, Fisher M, Che F, Dai H, Li D, Li R, Wang J, Wang Y, Zhao X, Li Z, Zheng H, Xiong Y, Meng X; TRACE-2 Investigators. Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial. Lancet. 2023 Feb 25;401(10377):645-654. doi: 10.1016/S0140-6736(22)02600-9. Epub 2023 Feb 9. [Accessed 20 Jun. 2024] Available at:
- Warach SJ, Dula AN, Milling TJ Jr. Tenecteplase Thrombolysis for Acute Ischemic Stroke. Stroke. 2020 Nov;51(11):3440-3451. doi: 10.1161/STROKEAHA.120.029749. Epub 2020 Oct 13. [Accessed 26 Jun. 2024] Available at:
Reviews
There are no reviews yet.